Immunocore Holdings plc ADR’s filing revealed that its Director BAKER BROS. ADVISORS LP acquired Company’s shares for reported $23.99 million on Mar 17 ’25. In the deal valued at $29.72 per share,807,338 shares were bought. As a result of this transaction, BAKER BROS. ADVISORS LP now holds 2,144,060 shares worth roughly $61.21 million.
Then, Brian Di Donato bought 100,000 shares, generating $3,000,000 in total proceeds.
Before that, Brian Di Donato bought 56,250 shares. Immunocore Holdings plc ADR shares valued at $1,638,511 were divested by the affiliate at a price of $29.13 per share.
Morgan Stanley downgraded its Immunocore Holdings plc ADR [IMCR] rating to an Equal-weight from a an Overweight in a research note published on December 13, 2024; the price target was decreased to $35 from $74. A number of analysts have revised their coverage, including Mizuho’s analysts, who decreased its forecast for the stock in mid November from “an Outperform” to “a Neutral”. UBS began covering IMCR with “Sell” recommendation on October 24, 2024. Guggenheim revised its rating on October 07, 2024. It rated IMCR as “a Neutral” which previously was an “a Buy”.
Price Performance Review of IMCR
On Tuesday, Immunocore Holdings plc ADR [NASDAQ:IMCR] saw its stock fall -3.35% to $28.55. Over the last five days, the stock has gained 1.75%. Immunocore Holdings plc ADR shares have fallen nearly -3.22% since the year began. Nevertheless, the stocks have fallen -52.30% over the past one year. While a 52-week high of $59.82 was reached on 01/27/25, a 52-week low of $23.15 was recorded on 04/09/25. SMA at 50 days reached $28.98, while 200 days put it at $31.59.
Levels Of Support And Resistance For IMCR Stock
The 24-hour chart illustrates a support level at 27.83, which if violated will result in even more drops to 27.10. On the upside, there is a resistance level at 29.35. A further resistance level may holdings at 30.14. The Relative Strength Index (RSI) on the 14-day chart is 46.80, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.97, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 80.94%. Stochastics %K at 31.07% indicates the stock is a holding.
The most recent change occurred on April 29, 2024 when Leerink Partners began covering the stock and recommended ‘”an Outperform”‘ rating along with a $74 price target.
